ONJUNU
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

ONJUNU Trademark

Serial Number: 88832134 • Registration: 7629139

ONJUNU is a trademark filed by Ascendis Pharma Bone Diseases A/S on March 12, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

Ascendis Pharma Bone Diseases A/S (3 trademarks)

Hellerup 2900 , DK

Entity Type: 99

Trademark Details

Filing Date

March 12, 2020

Registration Date

December 31, 2024

Published for Opposition

July 6, 2021

Goods & Services

Downloadable computer software and downloadable computer programs for use in providing medical advice and advice on medications for treatment, patient assistance and health insurance in the field of hypoparathyroidism, growth disorders, endocrine disorders and bone disorders; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, a downloadable software application for sharing information related to hypoparathyroidism, growth disorders, endocrine disorders and bone disorders and the treatment of hypoparathyroidism, growth disorders, endocrine disorders, bone disorders for use by patients with growth hormone disorders, hypoparathyroidism and skeletal dysplasia in the medical field of hypoparathyroidism, growth disorders, endocrine disorders and bone disorders; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, downloadable software that coordinates the delivery of health care services between health care providers, patients and those parties responsible for the payment of health care services, namely, downloadable software that allows individuals seeking medical education, information and services to locate a physician and treatment facility in their geographic area for medical treatment and allows physicians and health care professionals to communicate their credentials and specialization to patients and parties responsible for payment of healthcare services; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, downloadable software that enables health care providers to monitor patients, communicate clinical information relevant to a patient's care, provide and exchange information concerning patients and the health care services provided to patients; downloadable software, downloadable software applications and downloadable mobile applications for providing co-pay and other financial or medical access support; downloadable computer software for providing a communications platform enabling users to share health and healthcare information; downloadable software, downloadable software applications and downloadable mobile applications for the measurement of height, weight, blood pressure, serum calcium, blood glucose, and heart rate; downloadable software, downloadable software applications and downloadable mobile applications for providing, exchanging, retrieving and analyzing health and healthcare information; downloadable software for medical purposes, namely, for formatting, viewing and transmitting medical data collected and stored on hormone injection pens and pumps and between said injection pens and pumps and portable electronic devices; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, a downloadable software application for providing healthcare-related information, medication reminders, and tracking medication dosing history; the foregoing downloadable software related to pharmaceutical preparations for the treatment of hypoparathyroidism, growth disorders, endocrine disorders and bone disorders

Pharmaceutical preparations for the treatment of hypoparathyroidism; pharmaceutical preparations for the treatment of growth disorders, pharmaceutical preparations for the treatment of endocrine disorders, pharmaceutical preparations for the treatment of bone disorders; diagnostic preparations for medical use, namely, diagnostic preparations for identifying and detecting hypoparathyroidism, endocrine disorders and bone disorders

Medical devices for injection, dosage and control of pharmaceuticals, namely, medical devices for injection, dosage measurement and monitoring of pharmaceuticals for the treatment of hypoparathyroidism, growth disorders, endocrine disorders and bone disorders; syringes for medical purposes and for injections; syringes for injection for medical and surgical use, namely, syringes in the form of pens for surgical use; digitally connected medical devices for monitoring the dispensation of pharmaceutical preparations for use in connection with management of growth hormone disorders, hypoparathyroidism and skeletal dysplasia; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus for diagnostic purposes, namely, medicine dosage dispensers containing software featuring web-based medical information for physical and psychological examination and assessment of patients remotely and at a clinic; dosage management dispensers containing software for medical information management for guidance and control of medicines and for therapeutic use in web-based physical and psychological examination and assessment of patients remotely and at a clinic

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 31, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 31, 2024 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Dec 10, 2024 DP1B
NOTICE OF ALLOWANCE CANCELLED
Aug 26, 2024 IUCN
TEAS POST PUBLICATION AMENDMENT RECEIVED
Aug 26, 2024 EPPA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 29, 2024 EXRA
SOU EXTENSION 5 GRANTED
Feb 28, 2024 EX5G
SOU EXTENSION 5 FILED
Feb 28, 2024 EXT5
SOU TEAS EXTENSION RECEIVED
Feb 28, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 1, 2023 EXRA
SOU EXTENSION 4 GRANTED
Aug 30, 2023 EX4G
SOU EXTENSION 4 FILED
Aug 30, 2023 EXT4
SOU TEAS EXTENSION RECEIVED
Aug 30, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 24, 2023 EXRA
SOU EXTENSION 3 GRANTED
Feb 22, 2023 EX3G
SOU EXTENSION 3 FILED
Feb 22, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 22, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 25, 2022 EXRA
SOU EXTENSION 2 GRANTED
Aug 23, 2022 EX2G
SOU EXTENSION 2 FILED
Aug 23, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 23, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 26, 2022 EXRA
SOU EXTENSION 1 GRANTED
Jan 24, 2022 EX1G
SOU EXTENSION 1 FILED
Jan 24, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 24, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 31, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 6, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jul 6, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 16, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 1, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 1, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 1, 2021 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 26, 2021 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 3, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
May 3, 2021 GNSL
SUSPENSION LETTER WRITTEN
May 3, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 15, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 15, 2021 CRFA
ASSIGNED TO LIE
Mar 11, 2021 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 9, 2020 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 9, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jun 9, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jun 9, 2020 CNRT
ASSIGNED TO EXAMINER
Jun 4, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 18, 2020 NWOS
NEW APPLICATION ENTERED
Mar 16, 2020 NWAP